Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG [antithymocyte globulin] and Etanercept

Trial Profile

Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG [antithymocyte globulin] and Etanercept

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2010

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Etanercept
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2009 Inclusion and exclusion criteria amended from NCT.
    • 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Planned end date changed from 1 Dec 2007 to 1 Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top